Clinical Trials | Emory School of Medicine

Clinical trials are health-related studies in people that are closely supervised and carefully follow a pre-defined protocol. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Clinical trials may be done to see how a new treatment compares with the standard treatment or to see if a new treatment is safe and effective for a certain condition or disease. Participation in this type of research involves treatment with an experimental treatment or medical device, which may or may not provide a direct benefit to the individual. A clinical trial must be conducted for all new treatments before the FDA will approve the treatment for the public. The Emory ALS Center is actively engaged in research projects involving clinical trials of new medications to slow the progression of ALS.

Search for Clinical Trials

Clinical Trials Currently Enrolling

Research Study	Study Details/Eligiblity Information	Contact Person
COYA 302: C302-CLN-2301	Subcutaneous injection 5 days/week every 2 weeks Vital Capacity greater than 70% ALSFRS score greater than 35 at screening Disease onset fewer than 28 months prior to screening date Participation of 24 weeks plus optional 24-week extenstion	Katie Terrebonne Katherine.cummings@emory.edu
Tofersen in Adults with non-SOD1 ALS	Lumbar punctures required for drug administration Vital Capacity greater than 50% at screening Disease onset fewer than 24 months prior to screening Cannot be taking blood thinners Cannot have the genetic mutation SOD1 or FUS 36-week open-label participation period with possible extension	Karon Simmons Kmsimm2@emory.edu
PREVAiLS: PL101-ALS301	Oral medication Vital Capacity greater than 60% at screening Disease onset fewer than 18 months prior to screening Must be able to swallow oral medication 48-week double-blind study with optional 48-week open-label extension	Wanda Sanchez Wanda.sanchez@emory.edu
Zydus: UNITE-ALS	Oral medication Vital Capacity greater than 60% at screening ALSFRS score greater than 35 at screening Disease onset fewer than 24 months prior to screening 36-week double-blind study with optional 16-week open-label extension	Priya Karumanchi Plkarum@emory.edu